NCT02237937

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: HolsboerMaschmeyer NeuroChemie GmbH · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Accepted

Summary

The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene. Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	Paroxetine
DRUG	Sertraline
DRUG	Citalopram
DRUG	Venlafaxine
DRUG	Amitriptyline
DRUG	Escitalopram
DRUG	Amitriptylinoxide
DRUG	Nortriptyline
DRUG	Trimipramine

Timeline

• Start date: 2011-09-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2014-09-12
• Last updated: 2014-09-12

Locations

1 site across 1 country: Germany